Report on a newly approved orexin-mimicking oral therapy that targets narcolepsy's underlying biology and signals a shift in sleep disorder treatment approaches.
Key Takeaways
- “It’s the best thing that has ever happened to me,” says Tyler Chapman
- But it’s also being watched with anticipation by researchers
- For Chapman, a 19-year-old student at the University of Tennessee, Knoxville, the milestone is life changing